uploads/2018/05/stem-cell-163711_1280-1.jpg

How Much Upside Do Analysts See in Alexion Stock?

By

Updated

Alexion overview

Alexion Pharmaceuticals (ALXN) is a global biopharmaceutical company and a leader in complement inhibition. The company focuses its efforts on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

Article continues below advertisement

Analysts’ recommendations

Of the 19 analysts covering Alexion Pharmaceuticals in May, 18 have given the stock “buy” or higher ratings, while one has given it a “hold” rating. The mean rating for the stock is 1.74, and its target price is $158.53, which implies an upside potential of 30.4% over its closing price of $121.55 on May 15.

Peers’ ratings

Of the total 22 analysts covering Pfizer (PFE) in May, 11 have given the stock “buy” or higher ratings, nine have given it “hold” ratings, and two have given it “strong sell” ratings. The mean rating for the stock is 2.59, and its target price is $39.89.

Of the 30 analysts covering Celgene (CELG) in May, 15 analysts have given the stock “buy” or higher ratings. Fourteen analysts have given Celgene “hold” ratings, while one has given the stock a “sell” rating. The mean rating for the stock is 2.3, and its target price is $113.68.

Of the total 26 analysts covering Gilead Sciences (GILD) in May, 16 analysts have given the stock “buy” or higher ratings, while ten have given it “hold” ratings. The mean rating for the stock is 2.15, and its target price is $85.81.

In the next part of the series, we’ll take a look at recent developments at Alexion Pharmaceuticals.

Advertisement

More From Market Realist